Indeed, the seminal NEOSPHERE trial demonstrated that the addition of pertuzumab to trastuzumab (and chemotherapy) significantly increased the rate of pathological complete response (pCR) [[13], [14], [15]], in women with HER2-positive, locally advanced, inflammatory, or early early BC [9]. The gene discussed is ERBB2; the disease is breast cancer.